Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.

You may also be interested in...



Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

NDA for alogliptin submitted Dec. 27, Takeda tells “The Pink Sheet” DAILY, giving the drug an expected Oct. 27, 2008, PDUFA date with standard review.

Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

Takeda submitted an NDA for its dipeptidyl peptidase-4 inhibitor alogliptin (SYR-322) for type 2 diabetes Dec. 27, potentially positioning the Japanese pharma to be second to market with a drug in the class

Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

NDA for alogliptin submitted Dec. 27, Takeda tells “The Pink Sheet” DAILY, giving the drug an expected Oct. 27, 2008, PDUFA date with standard review.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel